Skip to main content
. 2021 Sep 17;56(1):76–82. doi: 10.2478/raon-2021-0036

Table 3.

Risk assessment

Number of patients (%)
Low risk 21 (53.8%)
Intermediate risk 5 (12.8%)
ESGO Clinical Risk Group High-intermediate risk 2 (5.1%)
High risk 10 (25.6%)
Advanced metastatic 1 (2.6%)
Low risk 22 (56.4%)
Intermediate risk 4 (10.3%)
Integrated molecular risk High-intermediate risk 3 (7.7%)
High risk 9 (23.1%)
Advanced metastatic 1 (2.6%)

ESGO = European Society of Gynaecological Oncology